Collaboration Agreement - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 28, 2022	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred revenue, description				Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $8.4 million to the Combined Performance Obligation and $3.6 million to the Development Activities Performance Obligation. In February 2022, the Company received $5.0 million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $5.0 million which was allocated to the two performance obligations as follows: $3.5 million to the Combined Performance Obligation and $1.5 million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of June 30, 2025, as all milestone amounts were fully constrained based on the probability of achievement.
Combined performance obligation		$ 8,400,000		$ 8,400,000
Development activities performance obligation		3,600,000		3,600,000
Collaboration revenue		183,000	$ 598,000	366,000	$ 1,130,000
Change in transaction price				0
Clinical Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment recognition in future periods to settlement of obligation		12,000,000		12,000,000
Milestone Achievements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment recognition in future periods to settlement of obligation	$ 5,000,000	5,000,000		5,000,000
Combined performance obligation	3,500,000	3,489,000		3,489,000
Development activities performance obligation		1,511,000		1,511,000
Collaboration revenue	$ 5,000,000	0		0		$ 0
Pre-Milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment recognition in future periods to settlement of obligation		12,000,000		12,000,000
Combined performance obligation		8,373,000		8,373,000
Development activities performance obligation		3,627,000		3,627,000
Post-Milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment recognition in future periods to settlement of obligation		17,000,000		17,000,000
Combined performance obligation		11,862,000		11,862,000
Development activities performance obligation		$ 5,138,000		$ 5,138,000